Skip to content
Search

Latest Stories

Submit Guest Post

Nesta gets Ravi Gurumurthy as new chief executive

NESTA, the UK’s leading innovation foundation, has announced that Indian-origin Ravi Gurumurthy will join as its new chief executive at the end of this year.

Gurumurthy, currently chief innovation officer and founder of the Airbel Center at the International Rescue Committee in New York, will replace Geoff Mulgan, who has led Nesta since 2011.


In his current role, Gurumurthy is responsible for the International Rescue Committee’s work in designing, testing, scaling products and services for people affected by the crisis in over 40 countries.

Mulgan oversaw the transition of Nesta from a non-departmental public body reporting to the government to an independent charity.

Under Mulgan’s leadership, Nesta expanded its scale of activity and today employs over 300 people.

Sir John Gieve, chair of Nesta’s Board of Trustees, said: “I am delighted to welcome Ravi to Nesta. His record of strategic thinking and innovation will help him build on Geoff Mulgan’s achievement in transforming Nesta from a quango to an independent charity promoting innovation for social good.

“There are huge opportunities today to use new technology and science to transform society for the better and to meet the challenges we face - from climate change to the loss of trust in big institutions. Under Ravi, I am confident Nesta will continue to nurture the best innovations, show that they work and collaborate to scale.”

Nesta is an organisation which uses innovative methods and investments to tackle big challenges facing society, from the frontiers of personalised healthcare to stretched public services and a fast-changing job market.

Working both nationally and globally in partnership with foundations, governments and corporate entities, Nesta spends over £40 million a year working to develop high-impact solutions that can change lives for the better.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less